Taiwan · Delayed Price · Currency is TWD Taiyen Biotech Statistics
Total Valuation
Taiyen Biotech has a market cap or net worth of TWD 6.31 billion. The enterprise value is 4.69 billion.
| Market Cap | 6.31B |
| Enterprise Value | 4.69B |
Important Dates
The last earnings date was Tuesday, March 24, 2026.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | Aug 20, 2025 |
Share Statistics
Taiyen Biotech has 200.00 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 200.00M |
| Shares Outstanding | 200.00M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | +0.49% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 6.32% |
| Float | 106.57M |
Valuation Ratios
The trailing PE ratio is 15.85.
| PE Ratio | 15.85 |
| Forward PE | n/a |
| PS Ratio | 1.91 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | 47.84 |
| P/OCF Ratio | 14.60 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.52, with an EV/FCF ratio of 35.56.
| EV / Earnings | 11.73 |
| EV / Sales | 1.42 |
| EV / EBITDA | 6.52 |
| EV / EBIT | 9.89 |
| EV / FCF | 35.56 |
Financial Position
The company has a current ratio of 2.87, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.87 |
| Quick Ratio | 2.37 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.17 |
| Debt / FCF | 0.95 |
| Interest Coverage | 127.50 |
Financial Efficiency
Return on equity (ROE) is 5.84% and return on invested capital (ROIC) is 7.34%.
| Return on Equity (ROE) | 5.84% |
| Return on Assets (ROA) | 3.56% |
| Return on Invested Capital (ROIC) | 7.34% |
| Return on Capital Employed (ROCE) | 6.49% |
| Weighted Average Cost of Capital (WACC) | 5.19% |
| Revenue Per Employee | 7.35M |
| Profits Per Employee | 888,593 |
| Employee Count | 487 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 4.89 |
Taxes
In the past 12 months, Taiyen Biotech has paid 100.28 million in taxes.
| Income Tax | 100.28M |
| Effective Tax Rate | 20.30% |
Stock Price Statistics
The stock price has decreased by -3.52% in the last 52 weeks. The beta is 0.18, so Taiyen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -3.52% |
| 50-Day Moving Average | 31.60 |
| 200-Day Moving Average | 32.10 |
| Relative Strength Index (RSI) | 47.88 |
| Average Volume (20 Days) | 104,130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Taiyen Biotech had revenue of TWD 3.31 billion and earned 399.87 million in profits. Earnings per share was 1.99.
| Revenue | 3.31B |
| Gross Profit | 1.34B |
| Operating Income | 474.19M |
| Pretax Income | 493.97M |
| Net Income | 399.87M |
| EBITDA | 710.17M |
| EBIT | 474.19M |
| Earnings Per Share (EPS) | 1.99 |
Balance Sheet
The company has 1.75 billion in cash and 125.52 million in debt, with a net cash position of 1.62 billion or 8.10 per share.
| Cash & Cash Equivalents | 1.75B |
| Total Debt | 125.52M |
| Net Cash | 1.62B |
| Net Cash Per Share | 8.10 |
| Equity (Book Value) | 6.81B |
| Book Value Per Share | 34.07 |
| Working Capital | 1.80B |
Cash Flow
In the last 12 months, operating cash flow was 432.05 million and capital expenditures -300.16 million, giving a free cash flow of 131.89 million.
| Operating Cash Flow | 432.05M |
| Capital Expenditures | -300.16M |
| Depreciation & Amortization | 235.98M |
| Net Borrowing | -88.26M |
| Free Cash Flow | 131.89M |
| FCF Per Share | 0.66 |
Margins
Gross margin is 40.54%, with operating and profit margins of 14.34% and 12.09%.
| Gross Margin | 40.54% |
| Operating Margin | 14.34% |
| Pretax Margin | 14.93% |
| Profit Margin | 12.09% |
| EBITDA Margin | 21.47% |
| EBIT Margin | 14.34% |
| FCF Margin | 3.99% |
Dividends & Yields
This stock pays an annual dividend of 1.40, which amounts to a dividend yield of 4.42%.
| Dividend Per Share | 1.40 |
| Dividend Yield | 4.42% |
| Dividend Growth (YoY) | 8.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 65.02% |
| Buyback Yield | -0.04% |
| Shareholder Yield | 4.39% |
| Earnings Yield | 6.34% |
| FCF Yield | 2.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 16, 2013. It was a reverse split with a ratio of 0.719181284.
| Last Split Date | Dec 16, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.719181284 |
Scores
Taiyen Biotech has an Altman Z-Score of 3.92 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.92 |
| Piotroski F-Score | 6 |